Executive Summary -

The inclusion of racial and ethnic groups in clinical trials has been a national priority for decades, but progress toward that end has been limited. When the Covid-19 pandemic threw into stark relief the underlying inequities in health care access (and thus in access to clinical trials), Congress and the Administration were moved to action. In parallel, trial sponsors, hospitals, and other stakeholders have been accelerating efforts to increase diverse populations’ access to clinical trials. Given the complexity of the challenge, much more action is needed at multiple levels and by all involved.